<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646111</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-15-OS-503-CTIL</org_study_id>
    <nct_id>NCT02646111</nct_id>
  </id_info>
  <brief_title>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors (&quot;PI&quot;) Failures</brief_title>
  <official_title>An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of triple therapy of AbbVie
      adults with chronic hepatitis C virus (&quot;HCV&quot;), who have not responded to prior treatment with
      protease inhibitors.

      The &quot;Triple therapy&quot; of AbbVie attacks various sites of the viral genome, thus increasing the
      potential efficacy of the treatment, especially for patients who have failed PI treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with genotype 1 HCV, who underwent past triple therapy (Telaprevir, Boceprevir or
      Simeprevir with Pegylated interferon / Ribavirin) and are non-responders, partial responders
      or in relapse - will be screened in all research centers up to 30 days before the first
      treatment.

      At the end of the initial assessment - the recruited participants will be allocated to
      different treatment groups in accordance with the hepatitis virus subtype 1a, 1b and presence
      of cirrhosis, as follows:

        -  Group A - genotype 1b without cirrhosis - 12 weeks of treatment *

        -  Group B - genotype 1b with cirrhosis - 12 weeks of treatment

        -  Group C - genotype 1a without cirrhosis - 12 weeks of treatment

        -  Group D - genotype 1a with cirrhosis - 24 weeks of treatment

      (* Only this group will not get Ribavirin)

      During the treatment period, participants will be asked to describe the treatment's
      tolerability (in terms of side effects) using self-administered questionnaires: SF-36, and
      WPAI Hep C v2.0.

      The follow up will also include physical assessments, side effects documentation, blood
      tests, abdominal Ultrasound and Fibroscan.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&quot;SVR&quot; (sustained virologic response) rates</measure>
    <time_frame>12 weeks after end of treatment</time_frame>
    <description>Sustained virologic response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&quot;SF&quot; (short-form)-36 health survey</measure>
    <time_frame>Day 1, weeks 4, 12, 24, 36.</time_frame>
    <description>psychometrically-based physical and mental health and a preference-based health utility index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WPAI Hep C v2.0 questionnaire</measure>
    <time_frame>Day 1, weeks 4, 12, 24, 36.</time_frame>
    <description>a scoring manual for work productivity and activity impairment assessment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Genotype 1b without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks without Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1b with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks with Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks with Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks with Ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12 weeks without Ribavirin</intervention_name>
    <description>12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.</description>
    <arm_group_label>Genotype 1b without cirrhosis</arm_group_label>
    <other_name>Triple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12 weeks with Ribavirin</intervention_name>
    <description>12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight &lt;75 kg, 1,200 mg weight&gt; 75 kg.</description>
    <arm_group_label>Genotype 1b with cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a without cirrhosis</arm_group_label>
    <other_name>Triple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>24 weeks with Ribavirin</intervention_name>
    <description>24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight &lt;75 kg, 1,200 mg weight&gt; 75 kg.</description>
    <arm_group_label>Genotype 1a with cirrhosis</arm_group_label>
    <other_name>Triple therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hepatitis C, genotype 1A or 1B.

          -  Documentation of PI failure of treatment at least 12 months prior to study entry.

          -  Patients with cirrhosis - (only patients with cirrhosis Child A with only 5 points).

        Exclusion Criteria:

          -  Inability to stay in the study for 36 weeks.

          -  Diagnosis of cross-contamination by HIV or Hepatitis B virus.

          -  Renal disfunction (creatinine clearance &lt;30 ml / min).

          -  Evidence of hepatic carcinoma.

          -  Another serious disease, which may interfere with the study.

          -  Pregnant / breast-feeding women.

          -  Men with pregnant partners.

          -  Drug or alcohol abuse in the six months preceding the study.

          -  Chronic liver disease other than hepatitis C (such as Primary biliary cirrhosis,
             Primary sclerosing cholangitis, Autoimmune hepatitis).

          -  Current other treatment for HCV.

          -  Past PI Failure due to adverse events.

          -  Patients with cirrhosis Child B.

          -  Patients with cirrhosis, who were at child B and improved to child A after treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oren Shibolet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oren Shibolet, MD</last_name>
    <phone>97236973984</phone>
    <email>orensh@tlvmc.gov.il</email>
  </overall_contact>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2016</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>Research and Development manager</investigator_title>
  </responsible_party>
  <keyword>&quot;Hepatitis C Virus&quot;</keyword>
  <keyword>&quot;Triple Therapy&quot;</keyword>
  <keyword>&quot;PI Failure&quot;</keyword>
  <keyword>&quot;Genotype 1&quot;</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

